Table 3.
Treatment details
| Median (IQR) or Mean +/− SD | |
|---|---|
| Median number of drugs in intensive phasea | 7 (6, 8) |
| Median number of drugs in continuation phasea | 5 (4, 5) |
| Median duration of amikacin treatment | |
| Daily dosing (days) | 139 (92, 173) |
| TIW dosing (days) | 115 (94, 150) |
| Total duration (months) | 7.2 (5.7, 8) |
| Median starting dose of amikacin (mg/kg) | |
| Daily | 8.9 (8, 10) |
| TIW | 8.1 (7.3, 9.2) |
| Median cumulative dose of amikacin (g) | 80.6 (61.7, 100.4) |
| Proportion of drug levels within target range | 89% (78–93%) |
| Median number of audiometry tests during amikacin treatment | 3 (1, 5) |
| Median total treatment duration (months) | 22 (20, 25) |
TIW Three times weekly
aPatients routinely received 5 drugs in the intensive phase and 4 drugs in the continuation phase. However, many patients required medication adjustments due to drug intolerances. The number displayed represents the median number of drugs trialed in order to establish the patient on an appropriate regimen